Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Genomic characterization unravelling the causative role of SARS-CoV-2 Delta variant of lineage B.1.617.2 in 2nd wave of COVID-19 pandemic in Chhattisgarh, India

Pushpendra Singh a, Kuldeep Sharma a, Priyanka Singh a, Anudita Bhargava a, Sanjay Singh Negi a,b, Pratibha Sharma a, Mayuri Bhise a, Manish Kumar Tripathi b, Atul Jindal c, Nitin M. Nagarkar d

a Department of Microbiology, All India Institute of Medical Sciences (AIIMS), Raipur, Chhattisgarh, India
b Department of Biophysics, All India Institute of Medical Sciences (AIIMS), New Delhi, India
c COVID Treatment Centre Incharge, All India Institute of Medical Sciences (AIIMS), Raipur, Chhattisgarh, India
d All India Institute of Medical Sciences (AIIMS), Raipur, Chhattisgarh, India

ARTICLE INFO

Keywords:
COVID-19
Second wave
Chhattisgarh
SARS-CoV-2
Delta variant

ABSTRACT

COVID-19 pandemic 2nd wave catastrophic effect in the state of Chhattisgarh, India, from where no exclusive genomic data yet published, has prompted us to undertake this study to unearth the causative variant. Whole-genome sequencing of SARS-CoV-2 isolated from COVID-19 infected nine vaccinated healthcare workers (HCW), thirty mild/moderate, seventeen severe, and twenty-seven deceased patients, was performed. The significant predominance of the SARS-CoV-2 variant of concern (VOC), Delta (lineage B.1.617.2) identified in sixty-four (77.1%) cases in contrast to B.1 and its sublineage in eleven (13.2%), variant under monitoring (VUM), Kappa (lineage B.1.617.1) in five (6.0%) and another VOC Alpha (lineage B.1.1.7) in three (3.6%) cases respectively ($p < 0.05$, $\chi^2 = 162.49$). 88.8% vaccine breakthrough, 60% mild/moderate, 94.4% severe and 81.5% dead patients were infected by Delta. Kappa presents exclusively in mild/moderate, Alpha in vaccine breakthrough, mild/moderate, and dead patient and B.1 and its sublineages in mild, severe, and dead patient categories. Delta variant spike mutation of T19R, G142D, E156G, L452R, and deletion (F157 and R158) helps in escaping antibody response, T478K and D614G enhance viral affinity with ACE2 receptor while P681R and D950N result in higher replication and transmissibility by cleaving S1/S2 at furin site. We conclude that Delta variant predominant role along with co-occurrence of Kappa, Alpha, and B.1 variant during COVID-19 2nd wave pandemic in Chhattisgarh may pose a potential threat of future outbreak through hybrid variant evolution. Thus, intensive genomic surveillance for monitoring variant evolution and a more efficacious vaccine against the Delta and Alpha variants are required.

1. Introduction

COVID-19 disease pandemic caused by a novel coronavirus (nCoV) named SARS-CoV-2 has so far posed the biggest public health challenge of the 21st century across the globe since its emergence in December 2019 from Wuhan, China. India, the second most affected country after the United States of America (USA), although managed first wave reasonably well, was unfortunately hit hard by 2nd wave of COVID-19 pandemic. 2nd wave of the pandemic that started around March 1, 2021 has accounted for eighteen million laboratory-confirmed cases and two hundred five thousand death at average daily death of over 2000 till 11th June 2021 [1]. The highest single-day number of cases rose to four hundred fourteen thousand on 6th May 2021. The worst affected states reported were Maharashtra, Karnataka, Kerala, Delhi, Andhra Pradesh, Telangana, Madhya Pradesh, and Chhattisgarh. This second wave was largely uncontrollable and unmanageable as it nearly crippled the nation’s healthcare system and led to an unprecedented rise in COVID cases and deaths. The severe shortage of hospitals beds, oxygen supply, and medicine have haunted humanity as overwhelmed crematoria were seen working round the clock to keep up with the pace of dead bodies.
Patients presented more with the clinical features of difficulty in breathing, fever, headache, myalgia, acute respiratory distress syndrome (ARDS), pneumonia, severe lung damage, gastrointestinal symptoms, and multiorgan failure. National guidelines have classified the patients into mild (normal saturation), moderate (pneumonia with no severe disease sign), and severe (severe pneumonia) [2]. Strict implementation of early diagnosis, treatment, contact tracing, lockdown, masking, and restricting social gathering has eventually brought down 2nd wave distratous effect under control by mid of June 2021.

The emergence of different variants of SARS-CoV-2 has been reported as the plausible explanation of 2nd wave [3,4]. As per WHO information latest on 25th November 2021, SARS-CoV-2 variants along with their country of origin, namely Alpha (B.1.1.7), United Kingdom, Beta (B.1.351), South Africa, Gamma (P.1), Brazil, and Delta (B.1.617.2), India have been classified as VOC while Kappa (B.1.617.1) variant was reclassified from earlier Variant of Interest (VOI) on 4th April 2021 to Variant under Monitoring (VUM) on 20th September 2021 (Fig. 1) [5]. The various other lineages along with their country of origin have been recognized under a group named ‘Alerts for Further Monitoring’ [5].

The causative nCoV variant of pandemic 2nd wave from various states of India has been reported [3,4]. Delta variant lineage B.1.617.2 outpacing B.1.1.7 in Delhi and B.1.617 identification from Maharashtra have been reported [3,4].

Chhattisgarh, one of the largest central states of India, was also severely affected by COVID-19 2nd wave, with majorly affected cities were Raipur (capital city of Chhattisgarh), Bilhail and Durg. Around 662,325 people were found infected, including 9275 deaths [1]. So, the need for whole-genome sequencing of SARS-CoV-2 isolated from COVID-19 patients categories of vaccine breakthrough, mild/moderate, severe and deceased from these districts of Chhattisgarh was utmost felt to unravel the variant/s responsible for this menace.

Accordingly, the present study was undertaken to genetically characterize SARS-CoV-2 strains obtained from COVID-19 patients in Chhattisgarh by sequencing the whole genome to identify accumulated viral mutation/s, strains, and lineages. The information, thus generated, would be utilized for formulating policies for effective management of the future course of the pandemic.

2. Materials and methods

2.1. Materials and methods

All India Institute of Medical Sciences (AIIMS), Raipur, and its Viral Research and Diagnostic Laboratory (VRDL) are the state nodal tertiary care treatment and diagnostic center for SARS-CoV-2 since the emergence of COVID-19 in the state of Chhattisgarh in March 2020. A randomly selected eighty-three (83) laboratory-confirmed cases of COVID-19 by real-time PCR showing Ct value of less than 25 for E and RdRP gene of SARS-CoV-2 were included in the study. These cases comprised fifty-three males (63.8%) and thirty (36.2%) females. Their collective mean age was 47.5 yrs being 45.9 and 50.2 years for males and females respectively (Supplementary Table). The majority of these cases were reported from the districts of Durg, Bilhail, and Raipur of Chhattisgarh, between 1st March to 5th May 2021 (Fig. 2). These cases comprised of vaccine breakthrough HCW (n = 09, 10.8%), mild/moderate symptomatic (n = 30, 36.14%), severe (n = 17, 20.4%) and deceased patients (n = 27, 32.7%). The viral RNA from all these cases were isolated from the collected combined clinical specimen of nasopharyngeal (NPS) and oropharyngeal swab (OPS) from every patient before anti-COVID treatment by following earlier described method [6]. All dead patients had a history of providing their specimen on the first day of hospitalization. Unfortunately, these patients were reported to succumb to COVID-19 during treatment. The institutional ethical approval obtained wide approval number 1453/IEC-AIIMSRPR/2021.

2.2. Whole genome sequencing of SARS-CoV-2

The isolated RNA from all the eighty-three cases was used for their cDNA and library preparation using QIAseq SARS-CoV-2 Primer Panel and QIAseq FX DNA Library Unique Dual Index (UDI) Kit from Qiagen GmbH, Germany. The enriched multiplexed amplicons were purified through AMPure XP bead (Beckman Coulter) and quantified using a Qubit dsDNA High Sensitivity Assay Kit (Invitrogen, USA) on Qubit 4 fluorometer (Invitrogen, USA). The fragmentation was performed to reduce median fragment size to approximately 250bp, and it was followed by end repairing. Sequencing adapters were then added to ligate to both ends of the DNA fragmented amplicons. The AMPure XP bead purification was done to remove excess of dNTPs, salts, free adapters and

Fig. 1. WHO Classified VOC Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1) and Delta (B.1.617.2) and VUM Kappa (B.1.617.1) showing specific signature mutational pattern.
enzymes. The purified ligated fragmented DNA amplicons were finally amplified to enrich the library with anti-adapter primers and then purified using AMPure XP beads. Library obtained were then checked for quality by Bioanalyzer 2100, Agilent, US using Agilent High Sensitivity DNA Chip kit, Germany. The fragmented library amplicons are quantified as described above. Thereafter, library was diluted to normalize and then pooled. Finally, the pooled library were sequenced in the MiSeq platform of Illumina, US, using MiniSeq Mid Output Reagent Cartridge from Illumina (300 cycles) in 150 × 2 PE read and FastQ only mode using MiniSeq local run manager.

2.3. Mutational and phylogenetic analysis

Individual consensus sequences of eighty-three nCoV isolates obtained using QIAGEN CLC Genomics Workbench version 21.0.4 were submitted in Global Initiative on Sharing Avian Influenza Data (GISAID) (Supplementary Table). The subsequent mapping and alignment of these sequences against the SARS-CoV-2 Wuhan variant reference sequence (GenBank ID NC_045512) were done to analyze mutational changes. The phylogenetic tree was constructed by the Neighbour-joining (NJ) method using MEGA-X version 10.2.

2.4. Structure modelling and evaluation

The 3D modeling of spike glycoprotein of the Wuhan reference prototype and our predominant identified lineage of Alpha, Delta and Kappa was performed using the SWISS-MODEL server and PyMOL to study the effect of the specific amino acid (AA) mutational changes [7].

3. Results

The whole-genome sequence analysis of SARS-CoV-2 from all eighty-three cases showed major nonsynonymous mutational AA changes primarily in viral receptor spike gene in comparison with reference Wuhan prototype (Table 1). Spike sequence alignment and phylogenetic analysis showed that sixty-four (77.1%) sequences belonged to VOC Delta variant of lineage B.1.617.2 and clade G/478 K.V1 (Figs. 3 and 4). Among these, forty-seven (47, 56.6%) sequences exhibiting eight nonsynonymous mutations (T19R, G142D, E156G, L452R, T478K, D614G, P681R and D950 N) and two deletions of F157del and R158del have shown two mutational group of with (twenty seven sequences) and without (twenty sequences) G142D mutation (Table 1). Seventeen sequences (20.4%) harbored six nonsynonymous changes of T19R, L452R, T478K, D614G, P681R, and D950 N and no deletions. Five (6.0%) sequences resembled Kappa variant (lineage B.1.617.1/clade G/452 R.V3) and exhibited changes of L452R, E484Q, D614G, and P681R. Three (3.6%) sequences belonged to the Alpha variant (lineage B.1.1.7/clade GR/501Y.V1) and showed a mutational pattern of N501Y, A570D, D614G, P681H, T716I, S982A, D1118H, and three deletions of H69, V70, and Y144. Importantly, eleven (13.2%) sequences belonged to B.3 lineage, and on its sub-lineages analysis, two sequences belonged to B.1 whereas others nine belonged to B.1 sublineage (02- B.1.216, 01- B.1.306, 01- B.1.326, 01- B.1.36.10, 01- B.1.36.17 and 03- B.1.36.29). These sequences were relatively found with fewer variations...
Table 1
Mutational pattern and GISAID allotted lineage of the eighty three sequences observed on alignment of spike region against reference Wuhan sequence.

| Lineage    | Mutation                  | Accession number          | Clinical status |
|------------|---------------------------|---------------------------|-----------------|
| B.1.1.7 (3) | H69del, V70del, Y144del, N501Y, A570D, D614G, P681R, T716I, S926A, D1118H | EPI_ISL_1731751, EPI_ISL_2098713, EPI_ISL_1914586 | Vaccinated (1)  |
|            |                           |                           | Dead (1)        |
|            |                           |                           | Mild (1)        |
| B.1.617.2 (64) | L452R, T478K, D614G, P681R, D950 N | EPI_ISL_2307104, EPI_ISL_2620739, EPI_ISL_1914588, EPI_ISL_2620743 | Dead (2)        |
|            |                           |                           | Mild (1)        |
|            |                           |                           | Severe (2)      |
| T19R, L452R, T478K, D614G, P681R, D950 N | EPI_ISL_2307110, EPI_ISL_2307123, EPI_ISL_2307126, EPI_ISL_2307134, EPI_ISL_2620742 | Dead (5)        |
|            |                           |                           | Severe (4)      |
| T19R, E156G, F157del, R158del, L452R, T478K, D614G, P681R, D950 N | EPI_ISL_1731755, EPI_ISL_2307136, EPI_ISL_1914592, EPI_ISL_2307120 | Vaccinated (2)  |
|            |                           |                           | Dead (3)        |
|            |                           |                           | Mild (9)        |
|            |                           |                           | Severe (6)      |
| B.1.36.17 (1) | L452R, E484Q, D614G, P681R | EPI_ISL_1914591, EPI_ISL_1914598, EPI_ISL_2098715, EPI_ISL_2098721, EPI_ISL_2307105, EPI_ISL_2307112-13, EPI_ISL_2307115, EPI_ISL_2307124, EPI_ISL_2307128 | Mild (5)        |
|            |                           |                           | Mild (5)        |
| B.1.36.29 (2) | L452R, E484Q, D614G, P681R | EPI_ISL_1731752-54, EPI_ISL_2307132-33, EPI_ISL_2307135, EPI_ISL_2307107, EPI_ISL_2620740, EPI_ISL_2620741, EPI_ISL_2307102, EPI_ISL_2307109, EPI_ISL_2307116, EPI_ISL_2307118, EPI_ISL_2307119, EPI_ISL_2307122, EPI_ISL_2307129, EPI_ISL_2307130, EPI_ISL_2307131, EPI_ISL_1914591, EPI_ISL_1914598, EPI_ISL_2098715, EPI_ISL_2098721, EPI_ISL_2307108, EPI_ISL_2620738, EPI_ISL_2098710-11, EPI_ISL_2307127 | Vaccinated (6)  |
|            |                           |                           | Dead (12)       |
| B.1.617.1 (5) | L452R, E484Q, D614G, P681R | EPI_ISL_1914585, EPI_ISL_1914587, EPI_ISL_1914589, EPI_ISL_2620740 | Mild (3)        |
|            |                           |                           | Mild (1)        |
|            |                           |                           | Mild (1)        |

Table 1 (continued)

| Lineage    | Mutation                  | Accession number          | Clinical status |
|------------|---------------------------|---------------------------|-----------------|
| B.1.216 (1) | D614G                     | EPI_ISL_1731756, EPI_ISL_1914579, EPI_ISL_1914589 | Dead (1)        |
|            |                           |                           | Mild (1)        |
| B.1.306 (1) | D614G                     | EPI_ISL_1914590 | Mild (1)        |
| B.1.326 (1) | D614G                     | EPI_ISL_2098711 | Severe (1)      |
| B.1.36.10 (1) | D614G                     | EPI_ISL_1914590 | Mild (1)        |
| B.1.36.17 (1) | N440K, D614G             | EPI_ISL_1914580 | Mild (1)        |
| B.1.36.29 (2) | N440K, D614G             | EPI_ISL_2098712, EPI_ISL_1914590, EPI_ISL_1914582 | Dead (1)        |
|            |                           |                           | Dead (2)        |

Notable mutational variations were noticed among the four groups of vaccine breakthrough HCW, symptomatic mild/moderate, severe, and dead patients (Figs. 5 and 6). In the first category of the vaccinated health care worker, eight were found infected with Delta variant while one was infected with Alpha nCoV variant (Figs. 5A and 6). The Delta variant in all eight cases harbored the nonsynonymous mutations of T19R, E156G, L452R, T478K, D614G, P681R, D950 N, and two deletions of F157del and R158del, respectively. Among them, six vaccinated cases showed one more G142D AA change, while the other two vaccinated cases did not exhibit this mutation (Fig. 4A). The one case of Alpha nCoV variant was found with mutations as described above (Figs. 5A and 6).

Among mild/moderate symptomatic cases, eighteen cases were found infected by Delta, five by Kappa, one by Alpha and six by nCoV B.1 variant having various sublineages respectively (Fig. 6). The sublineages revealed two infected with B.1.36.29, while one case each was infected with sublineage of B.1.1.216, B.1.36.17, B.1.36.10, and B.1.1.306 (Table 1). The Delta variant in eighteen cases showed similar mutational pattern as described above except four cases without harbouring two deletions (F157del and R158del) and one nonsynonymous mutation of E156G, thirteen cases without G142D and one case without T19R mutation were observed (Table 1, Fig. 5B). The important observation included exclusive finding of Delta variant with its earlier described characteristic mutational pattern only in the mild/moderate symptomatic cases (Fig. 5B). The one case of Alpha variant exhibited similar mutational changes as observed in Alpha variant infected vaccinated patients. In the rest six cases of different B.1 sublineages, the mutation of D614G was found in all cases, while N440K was found in three cases (Fig. 5B).

Among seventeen severe symptomatic cases, sixteen cases were found infected with Delta variant while only one case by B.1.1.326 variant (Figs. 5C and 6). Delta variant exhibited L452R, T478K, D614G, P681R, and D950 N mutations in all seventeen cases, while the frequency of other mutations varied as T19R and G142D were detected in fourteen and four cases respectively. E156G and two deletions (F157del and R158del) were observed in ten patients infected by the Delta variant. One case infected by B.1.1.326 harbored a sole mutation of D614G (Fig. 5C).

In twenty-seven deceased patients, the majority of twenty-two cases succumbed to the Delta variant (Figs. 5D and 6). Of these, as D614G was dominantly found in all sequences, and only four sequences showed additional changes of N440K while one sequence exhibited two more changes of P681R and D950 N (Table 1). So our result showed that the Delta variant of lineage B.1.617.2 has significantly outpaced all other variants of Alpha (B.1.1.7), Kappa (B.1.617.1), and B.1 other variant with its predominant occurrence of 77.1% while other lineages were observed in variable distribution frequency of 23%.
cases, one case was found infected with Alpha variant while the remaining four were found infected with B.1 lineage of variable sub-lineage (B.1-two cases, B.1.1.216-one case and B.1.36.29-one case) (Table 1). The mutational analysis found that the Delta variant exhibited all designated mutational AA changes except G142D in twelve, T19R in twenty, and E156G and two deletions (F157del and R158del) were observed in fifteen cases respectively (Fig. 5D). The Alpha variant in one case has shown the same mutation as described for other patients categories earlier. The remaining four cases infected with B.1 lineage have shown the sole common mutation of D614G (Fig. 5D).

Overall, only D614G mutation was found in all cases with 100% occurrence among eighty-three sequences. L452R, T478K, and P681H/R were seen in 69 (83.1%), 65 (78.3%), and 73 (87.9%) sequences, respectively (Fig. 5E). D950N was detected in 64 cases with a frequency of 77.1%. The rest of the other prominent mutations, namely T19R, G142D were observed in 59 (92.2%) and 28 (33.7%) sequences, whereas E156G and two deletions (F157del and R158del), were detected in forty-seven (73.4%) sequences respectively (Fig. 5E).

The whole-genome analysis also showed mutations in specific genes/regions other than spike either among all the lineages or restricted exclusively to Delta and/or Kappa variant (Table 2). Notably, all variants showed P323L mutation in nonstructural protein (NSP) 12 encoding RNA dependent RNA polymerase (RdRP) gene, and Delta variant exclusively showed I82T mutation in membrane protein-encoding gene.

The 3D modeling of spike glycoprotein has depicted positional changes in AA residue of SARS-CoV-2 variant of VOC and VUM in comparison to the Wuhan prototype (Fig. 7A–D). L452R, T478K, N501Y and A570D mutations were located in spike protein receptor binding domain (RBD). N-terminal domain (NTD) region of these sequences harbored T19R, G142D, and E156G, respectively along with deletions of...
H69, V70, Y144, F157 and R158del. Notable mutation D614G was identified distally to the furin cleavage site. Mutations of P681 R/H, D950 N, T716I, S982A, Q1071H, and D1118H were located in proximity to the S1/S2 cleavage site. VOC B.1.1.7 (n = 3) and B.1.617.2 (n = 64) exhibited substitution of same codon residue by different AA namely P681H and P681R (Fig. 7 E, F). The P681R mutation in B.1.617.2 appears to disrupt the cleavage site by changing the Proline, a non-polar AA (imino acid group), to Arginine, a polar positively charged AA (guanidino group) (Fig. 7 E and F). Similarly, P681H mutation in B.1.617.2 also changed the furin cleavage site by substituting Proline to Histidine, a polar AA (imidazole group) (Fig. 7 E and F). Both substituted Arginine and Histidine AA has a basic side chain with which they tend to bind protons; gaining a positive charge in the process to eventually result in the improved rate of membrane fusion, virus entry, and higher transmissibility [8, 9].

4. Discussion

The phylogenetic analysis identified our eighty-three sequences belonged to 10 different PangoLIN lineages, all within clade G. These lineages were dominated by Delta and followed by B.1 and its sublineages, Kappa and Alpha. Therefore Delta variant, B.1.617.2 of clade G/478K.V1 with 77.1% presence was the predominant lineage that has outpaced all other co-circulating lineages to become the chief causative variant responsible for COVID-19 2nd wave in Chhattisgarh. INSACOG, a national multi-agency consortium of Genome Sequencing Laboratories set up by the Government of India on 8th July 2021 has also reported the presence of VOC B.1.617.2 from 174 districts in 35 states and union territories in India, with the highest numbers reported from Maharashtra, Delhi, Punjab, Telangana, West Bengal, and Gujarat. B.1.617 was detected initially from Maharashtra and from there it appeared to spread to other states [3]. High transmission of B.1.617.2 lineage has outpaced the earlier circulating lineage of B.1.1.7 between January to February 2021 to infect larger number of people at Delhi during COVID-19 2nd wave [4]. SARS-CoV-2 of other Pango lineage were observed in lesser proportion in Chhattisgarh. Kappa B.1.617.1 (G/452 R.V3) and Alpha B.1.1.7 lineage (GR/501Y.V1) were observed in 6 and 3.6% cases, respectively. Furthermore, the co-occurrence of B.1 and its sub lineage in 13.2% of the sequences has indicated that the multiple lineages in circulation underwent convergent evolution during the COVID-19 2nd wave at Chhattisgarh.

Analysis of individual patients groups revealed 88.8% vaccine breakthrough, 60% mild/moderate, 94.1% severe, and 81.4% dead patients were infected by Delta variant. Epidemiological and genomic data of the eighty-three cases revealed that males were twice more infected than females. The majority of the infected cases were adults with a collective mean age of 47.49 yrs. Since Delta variants was detected in all different patient groups, no specific mutation inclination pattern or change was seen in severe or dead cases. So, it appeared that Delta variant characteristic signature mutations enhancing virus penetration and transmissibility were present in all individuals infected by Delta variant.
Fig. 5. Schematic representation of the mutational patterns in the four studied groups. A) Vaccinated health care workers (B) Symptomatic cases with mild/moderate disease (C) Symptomatic cases with severe disease (D) Dead patients and (E) Total.
transmissibility and pathogenicity and various other factors plausibly could explain severity or death in infected patients. Probable factors includes more lethal and highly transmissible Delta variant, a higher proportion of patients with underlying diseases, delay in diagnosis and hospitalization, unavailability of oxygen beds, and antiviral remdesivir. In the absence of any substantial inhibition, Delta variant rampantly colonized and damaged the lung. The exaggerated immune response mediated viral entry in other organs had further worsened the clinical conditions leading to severity and death due to ARDS or multiple organ failure. Unfortunately, the lack of complete follow-up clinical data did not allow us to correlate which factors aggravated different nCoV variants to cause severity and death.

In vaccination breakthrough cases showing mild infection, eight cases were infected by VOC B.1.617.2, while one was infected with B.1.1.7 lineage. This indicated that vaccine although not giving cent percent efficacy yet the fact of these patients showing only mild flu like symptom and not requiring hospitalization suggest that vaccination reduces the severity of the disease and should be carried out at war foot scale to vaccinate at least 70% population to ensure herd immunity. Further, vaccine developers also need to work on improving the efficacy of their present vaccination especially against Delta and Alpha variant.

An earlier study substantiated our finding of vaccine breakthrough cases, reporting 86.69% presence of Delta variant in infected vaccinated cases [10]. While Delta variant was observed in all four different patients categories, Kappa variant presence was only noticed in mild cases whereas Alpha variant in vaccine breakthrough, mild and dead cases. B.1 and its various sublineages were also detected in mild, severe, and dead cases. These findings may suggest that Delta, Alpha, B.1 and its sublineage are capable of causing severe infection and death in case of delayed diagnosis/treatment.

The nonsynonymous mutations observed in the spike gene were analyzed for their biological significance. Various mutations in spike protein of B.1.617.2 has inflicted the enhanced pathogenicity and transmissibility. Mutation of T19R, G142D, T478K, D950 N, and two deletions of F157 and R158 have been exclusively seen in the Delta variant, while other mutations namely L452R, D614G, and P681R in Delta variant was also found in other lineages reported in our study. T19R, G142D, E156G, and two deletions of F157 and R158 located within NTD has altered a recognized monoclonal antibody (mAb) recognition site N1 and N3 loop to help the virus in escaping antibody response [4,11]. The two significant deletions of F157 and R158 and one substitution E156G at NTD antigenic supersite in Delta variant have also been reported as ‘surge-associated mutations’ to increase infectivity by 10 fold due to mechanism of evading neutralizing antibodies [12,13]. L452R, T478K occurred in the RBD region of the spike protein. L452R has already been earlier reported for escape from antibody immune response as these mutations reduces the antibody binding to mutation variants compared to wild type [3]. An earlier study also reports that L452R mutation had abolished the neutralizing effect of 14 mAb out of around 35 RBD mAb [14]. L452R mutation was further reported to help in virus escape from cellular immunity induced with human leukocyte antigen (HLA)-24 to eventually result in increased viral replication and infectivity [15]. It was reported earlier that in T478K, mutated Lysine reduced the gap to the extent of 8.3 Å between spike and ACE2 receptor in comparison to wild prototype which with threonine measured as 10 Å to eventually enhance the viral affinity with ACE2 receptor. This may be helpful in hyper transmissibility.
original Wuhan nCoV [4]. It has been identified distally to the furin cleavage site to enhance viral cell entry efficiency by increased affinity to ACE2 cell receptors [4]. This may lead to increased viral loads in the upper respiratory tract COVID-19. D614G mutation earlier reported producing an allosteric conformational change in the furin cleavage site to result in RBD opening [18]. The detection of D614G in all our reported lineages has strongly suggested that the emergence of all variants of SARS-CoV-2 occurred after the worldwide adaptation and rise of the D614G mutants. The two mutations of P681R, D950 N were found close to the S1/S2 cleavage site to enhance viral replication and transmissibility [19]. P681R was seen in Delta, whereas P681H was observed in Alpha variant. Although both mutations increase the basicity of the S1–S2 poly-basic stretch at the furin cleavage site, P681R has inflicted more advantage to the virus by cleaving more efficiently S1/S2 cleavage at the furin site leading to the enhanced entry of the virus into host cells. This may augment the rate of viral membrane fusion and internalization into the host cell to result in higher replication and transmissibility, facilitating Delta enhanced fitness over Alpha variant [20]. Both L452R and P681R were reported to also aid in escaping the virus from specific monoclonal antibody responses [14,21–23]. In totality, these nonsynonymous mutations in B.1.617.2 were the appropriate reason for its higher statistical significance occurrence in patients with all sorts of clinical features from mild to moderate, severe, and dead.

Kappa variant B.1.617.1 was only detected in five mild cases. The Kappa variant harbored only four mutations of L452R, E484Q, D614G, and P681R (Fig. 5B). The combined mutations of L452R and E484Q have already been earlier reported for escape from antibody immune response [3,24]. However, the lack of other mutations in Kappa variant has restricted its infectivity lower than Delta variant.

Alpha variant B.1.1.7 was found in one case each from vaccine breakthrough, mild and dead patient category showing nonsynonymous mutations of N501Y, A570D, D614G, P681H, T716I, S982A, D1118H and three deletions of H69del, V70del, and Y144del. N501Y, A570D, and three deletions are characteristic signature mutations of the Alpha variant. N501Y and A570D at critical RBD enhance viral interaction with ACE2 human receptor [4]. Further, P681H in Alpha disrupts the furin cleavage site by changing the Proline to improve the rate of membrane fusion, virus entry, and higher transmissibility, albeit less efficiently than Delta variant manifesting P681R [20]. During 2020 year-end, subsequent to the first predominant mutation of D614G in the prototype variant, many countries have started noticing the first VOC B.1 and its sublineages showing the persistent presence of D614G in their all sublineages of B.1, B.1.1.216, B.1.36.10, B.1.1.306, B.1.1.326, B.1.36.29 and B.1.36.17 confirms its paramount importance in increasing virion spike density and infectivity [27]. Only B.1.36.29 and B.1.36.17 also showed N440K mutation, which was reported earlier as prone to immune escape. N440K mutation, since first detected from the state of Andhra Pradesh, has been reported in around six percent of the nCoV sequenced across India [28].
CRediT authorship contribution statement

Pushpendra Singh: Formal analysis, Investigation, Methodology, Writing – original draft. Kuldeep Sharma: Methodology, Formal analysis, Data curation. Priyanka Singh: Resources. Anudita Bhargava: Writing – review & editing, Validation, Resources. Sanjay Singh Negi: Conceptualization, Project administration, Supervision, Visualization, Writing – review & editing. Pratibha Sharma: Writing – review & editing, Writing – original draft. Mayuri Bhise: Software. Manish Kumar Tripathi: Visualization, Validation, Software, Methodology. Atul Jindal: Resources, Writing – review & editing. Nitin M. Nagarkar: Resources.

Declaration of competing interest

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Dr. Sanjay Singh Negi reports financial support was provided by All India Institute of Medical Sciences (AIIMS), Raipur. Dr. Snajay Singh Negi reports a relationship with All India Institute of Medical Sciences (AIIMS), Raipur that includes: Dr. Sanjay Singh Negi has patent pending to NA. NA.

Acknowledgment

(COVID-19/2020/34) All India Institute of Medical Sciences (AIIMS), Raipur.

References

[1] Government of India Ministry of Health & Family Welfare. COVID-19 India state wise status: Chhattisgarh. https://www.mohfw.gov.in/2021, https://www.mohfw.gov.in/covid-19 (accessed August 1, 2021).

[2] Government of India Ministry of Health & Family Welfare. Clinical management protocol for COVID-19. Clin Guid Manag Adult COVID-19 Patients 2021–1–22. https://www.mohfw.gov.in/ (accessed August 10, 2021).

[3] S. Cherian, V. Potdar, S. Jadhav, P. Yadav, N. Gupta, M. Das, et al., Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra, India, BioRxiv 2021 (2021), https://doi.org/10.1101.04.22.440952, 04.22.440932.

[4] M.S. Dhar, R. Marwal, V.S. Radhakrishnan, K. Ponnusamy, B. Jolly, R.C. Bhyoir, et al., Genomic characterization and Epidemiology of an emerging SARS-CoV-2 variant in Delhi, India, MedRxiv 2021 (2021), https://doi.org/10.1101/2021.06.02.21258076, 06.02.21258076.

[5] WHO. Weekly epidemiological update on COVID-19 – 10 August 2021, Edition 52. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19-2021–10-august-2021.-date-2021-pages-1–22.

[6] K. Sharma, P. Aggarwal, D. Gandhi, A. Mathias, P. Singh, S. Sharma, et al., Comparative analysis of various clinical specimens in detection of SARS-CoV-2 using rtRT-PCR in new and follow up cases of COVID-19 infection: quest for the best choice, PLoS One 16 (2021), e0249408.

[7] M. Biasini, S. Bienert, A. Waterhouse, K. Arnold, G. Studer, T. Schmidt, et al., SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information, Nucleic Acids Res. 42 (2014) W252-W258, https://doi.org/10.1093/nar/gku346.

[8] T.P. Peacock, C.M. Sheppard, J.C. Brown, N. Goonawardane, J. Zhou, M. Whiteley, et al., The SARS-CoV-2 variants associated with infections in India, B.1.617, show enhanced spike cleavage by furin, BioRxiv 2021 (2021), https://doi.org/10.1101/2021.04.28.446163.5.

[9] E. Lasèk-Nessiebuïjt, J. Pata, E. Schneider, K. George, A tale of three SARS-CoV-2 variants with independently acquired P681H mutations in New York State, MedRxiv 2021 (2021), https://doi.org/10.1101.03.21.21525265, 03.21.21525265.

[10] N. Gupta, H. Kaur, P. Yadav, L. Mukhopadhyay, R.R. Sahay, A. Kumar, et al., Clinical characterization and Genomic analysis of COVID-19 breakthrough infections during second wave in different states of India, MedRxiv 2021 (2021), https://doi.org/10.1101/2021.05.23.21256768.

[11] N. Suryadevara, S. Shrirahi, P. Gilchik, L.A. VanBlargan, E. Binshtok, S.J. Zott, et al., Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein, Cell 184 (2021) 2316–2331, https://doi.org/10.1016/j.cell.2021.03.092, e15.

[12] K.R. Marccharthy, L.J. Rennick, S. Nambulli, L.R. Robinson-McCarty, W.G. Bain, G. Haidar, et al., Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape, Science 80 (371) (2021) 1139, https://doi.org/10.1126/science. abe6950. LP – 1142.

[13] A.J. Venkatkarthikshan, P. Anand, P. Lenehan, P. Ghosh, R. Suratekar, A. Siroha, et al., Antigenic characterization of SARS-CoV-2 is linked to surges in COVID-19 community transmission and vaccine breakthrough infections, MedRxiv 2021 (2021), https://doi.org/10.1101/2021.05.23.21256768. 05.23.21256768.

[14] M. McCallum, J. Bassi, A. De Marco, A. Chen, A.C. Walls, J. Di Iulio, et al., SARS-CoV-2 immune evasion variant B.1.427/B.1.429, BioRxiv Prepr Serv Biol (2021) 2021, https://doi.org/10.1101/2021.03.31.437925, 03.31.437925.

[15] C. Motozono, M. Toyoda, J. Zahradnik, T. Ikeda, A. Saito, T.S. Tan, et al., An emerging SARS-CoV-2 mutant evading cellular immunity and increasing viral infectivity, BioRxiv 2021 (2021), https://doi.org/10.1101.04.28.428208, 04.02.428208.

[16] X. Deng, M.A. Garcia-Knight, M.M. Khalid, V. Serpellita, C. Wang, M.K. Morris, et al., Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant, Cell 2021 (2021), https://doi.org/10.1016/j.cell.2021.04.025.

[17] S. Di Giacomo, D. Mercatelli, A. Rakhimov, F.M. Giorgi, Preliminary report on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Spike mutation T478K, J. Med. Virol. (2021), https://doi.org/10.1002/jmv.27062 n/a.

[18] S.M.C. Gobeil, K. Janowska, S. McDowell, K. Mansouri, R. Parks, K. Manne, et al., D614G mutation alters SARS-CoV-2 spike conformation and enhances protease cleavage at the S1/S2 junction, Cell Rep. 34 (2021) 108630, https://doi.org/10.1016/j.celrep.2020.108630.

[19] T. Lemmin, D. Kalbermatter, D. Harder, P. Plattet, D. Fotiadis, Structures and dynamics of the novel S1/S2 protease cleavage site loop of the SARS-CoV-2 spike glycoprotein, J. Struct. Biol. X 4 (2020) 100038, https://doi.org/10.1016/j.jsbxb.2020.100038.

[20] Y. Liu, J.J. Liu, B.A. Johnson, H. Xia, Z. Ku, C. Schindewolf, et al., Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant, BioRxiv 2021 (2021), https://doi.org/10.1101.08.12.456173, 08.12.456173.

[21] Q. Li, J. Nie, J. Wu, L. Zhang, R. Ding, H. Wang, et al., SARS-CoV-2 501Y.V2 variants lack higher infectivity but do have immune escape, Cell 184 (2021) 2362–2371.
[22] V.-V. Edara, L. Lai, M.K. Sahoo, K. Floyd, M. Sibai, D. Solis, et al., Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant, BioRxiv Prepr Serv Biol (2021) 2021, https://doi.org/10.1101/2021.05.09.443299, 05.09.443299.

[23] P.D. Yadav, G.N. Sapkal, P. Abraham, R. Ella, G. Deshpande, D.Y. Patil, et al., Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees, Clin. Infect. Dis. (2021), https://doi.org/10.1093/cid/ciab411.

[24] S. Jangra, C. Ye, R. Rathnasinghe, D. Stadlbauer, H. Alshammary, A.A. Amoako, et al., SARS-CoV-2 spike E484K mutation reduces antibody neutralisation, The Lancet Microbe (2021), https://doi.org/10.1016/S2666-5247(21)00068-9.

[25] A.J. Greaney, A.N. Loes, K.H.D. Crawford, T.N. Starr, K.D. Malone, H.Y. Chu, et al., Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies, Cell Host Microbe 29 (2021) 463–476, https://doi.org/10.1016/j.chom.2021.02.003, e6.

[26] S.A. Kemp, B. Meng, L.A.T.M. Ferriera, R. Datir, W.T. Harvey, G. Papa, et al., Recurrent emergence and transmission of a SARS-CoV-2 spike deletion H69/V70, BioRxiv 2021 12 (14) (2020), 422555, https://doi.org/10.1101/2020.12.14.422555.

[27] J.A. Plante, Y. Liu, J. Liu, H. Xia, B.A. Johnson, E.G. Lokuganae, et al., Spike mutation D614G alters SARS-CoV-2 fitness, Nature 592 (2021) 116–121, https://doi.org/10.1038/s41586-020-2895-3.

[28] S. Srivastava, S. Banu, P. Singh, D.T. Sowpati, R.K. Mishra, SARS-CoV-2 genomics: an Indian perspective on sequencing viral variants, J. Biosci. 46 (2021) 22, https://doi.org/10.1007/s12038-021-00145-7.

[29] S. Imlivar, F. Abdul, S. Acosta-Gutierrez, C. Estarellas, I. Galdadas, M. Casimir, et al., Concurrent mutations in RNA-dependent RNA polymerase and spike protein emerged as the epidemiologically most successful SARS-CoV-2 variant, Sci. Rep. 11 (2021) 13705, https://doi.org/10.1038/s41598-021-91662-w.

[30] L. Shen, J.D. Bard, T.J. Triche, A.R. Judkins, J.A. Biegel, G. Gai, Emerging variants of concern in SARS-CoV-2 membrane protein: a highly conserved target with potential pathological and therapeutic implications, Emerg. Microb. Infect. 10 (2021) 885–893, https://doi.org/10.1080/22221751.2021.1922097.